CEO Update - 8 July 2024

Europe’s largest Series A biotech spin-out this year

It is a fantastic way to start the week with news of Europe’s largest Series A biotech spin-out this year from the UK. Congratulations to Myricx Bio, an Imperial College London and Francis Crick Institute spin-out company focusing on a novel class of payloads for antibody-drug conjugates (ADCs), for announcing their Series A financing of £90 million.

The round was co-led by Novo Holdings and Abingworth, with additional new investors British Patient CapitalCancer Research Horizons and Eli Lilly and Company participating alongside founding investors Brandon Capital and Sofinnova Partners. With this significant funding, Myricx now has the resources to transition from a virtual company to a fully-fledged R&D company. They will establish their own laboratories, build an in-house R&D team, and expand their management capability.

It's just the type of economic growth story the incoming Labour government has put at the heart of its policy programme and shows how with productive finance available UK life sciences can compete internationally in a growth industry of the future.

UK General Election

General Election - new government

Steve at Gov.jpg

The new UK government is forming this week following Labour’s landslide victory at the General Election last week. New Prime Minister Kier Starmer has appointed his cabinet, with all the key roles going to those we had expected. I’ve already written to Rachel Reeves, the new Chancellor, Wes Streeting, the new Health Secretary, and Peter Kyle, the new Science Secretary.

One very welcome surprise appointment is Sir Patrick Vallance as the new Science Minister in the House of Lords. We know him well, having worked closely with him in his role as Chief Scientific Advisor to government during the pandemic and on setting up the Vaccine Taskforce during the COVID-19 pandemic.

The incoming Labour government has been elected with a clear mandate to prioritise economic growth and its manifesto identified the life sciences sector as a great British industry primed to deliver it.

The Labour Party’s life sciences sector plan, published in February, lays the groundwork for a new life sciences strategy. Addressing the chronic underinvestment by the UK pension industry in start-ups and scale-ups, and fine-tuning the tax system to support innovation-led growth, will be the first orders of business.

New Parliament

Parliament is reconvening this week with 334 new MPs out of the 653 elected. Among them is a fantastic cohort of scientifically engaged individuals, including biomedical researchers and biotech leaders, who are now taking their places on the green benches in the Palace of Westminster. Their knowledge and understanding of innovation will be crucial as the UK navigates a new global era where science and innovation will determine its economic and social progress.

This significant changing of the political guard means many familiar faces are no longer in Parliament, and we now have a whole new cadre of MPs to engage with. If you know any of the new parliamentarians and think they may be interested in life sciences, we’d love to hear about your connections as we plan our Parliament Day for November.

Join our webinar this Wednesday

We’ll aim to pull together our thoughts and insights on what the new government means for our sector for our webinar this Wednesday where we’ll go through in more detail who the key new players are and recap on their early utterances and stated priorities.

Nicola Baker Munton memorial service

The memorial service for the founder of Strategem IPM and longstanding BIA member Nicola Baker Munton is at 2 pm on Friday, 12 July at Lavenham Church in Suffolk (CO10 9SA). Nicola started Stratagem in 1999 after identifying a need for in-house-style IP advice to early-stage biotech companies. Nicola’s family ask anyone coming to send a message to [email protected] so they have an idea of numbers. 

BIA Summer party

I’m looking forward to seeing many of you at the premier event of the UK life science summer scene, the BIA Summer Party, this Thursday at 7 pm. It’s set to be a fantastic event, and with the excellent space at the Langham Hotel, it will be great regardless of the weather.


Steve Bates Headshot.png



Steve Bates OBE
CEO, BioIndustry Association

More news and updates 

ImmuONE is celebrating triple triumph at the inspiring herts awards 2024

We’re proud to announce that ImmuONE took home the prestigious award for ‘Business of the Year – North Herts’, which was awarded to us for consistent growth, robust financial performance, and unwavering commitment to staff and innovation. From the pool of winners, there was also a special recognition category which honoured ImmuONE with the ‘Inspiring Business of the Year’ award for making the biggest innovation in Hertfordshire.

Cryoport systems officially launches global supply chain hub in Stevenage

Cryoport, Inc a global leader in innovative supply chain solutions for the cell and gene therapy industry, is thrilled to announce the official launch of the Cryoport Systems state-of-the-art Global Supply Chain Hub in Stevenage, U.K.

Microbiotica to present positive update on manufacturing progress of its live biotherapeutic products

Microbiotica, a biopharma company developing a pipeline of orally-delivered precision microbiome medicines announces that Adam Wilkinson, its Vice President of Pre-Clinical Development, will present an overview of the company’s successful product manufacturing campaigns ahead of its forthcoming melanoma and ulcerative colitis clinical studies at the 9th Microbiome Movement Drug Development Summit, on 11 July, in Boston, USA, together with Claire Derlot, CBO from its GMP manufacturing partner Biose Industrie.

Milner Institute celebrates success of 2024 Pitch Day and therapeutics symposium

The Milner Therapeutics Institute were delighted to host two sell-out events in Cambridge that brought academics, investors, pharma and biotech companies together.

CEO Update - 8 July 2024

It is a fantastic way to start the week with news of Europe’s largest Series A biotech spin-out this year from the UK. Congratulations to Myricx Bio, an Imperial College London and Francis Crick Institute spin-out company focusing on a novel class of payloads for antibody-drug conjugates (ADCs), for announcing their Series A financing of £90 million.

Moa harvests global deal for new herbicide

Moa Technology has signed a major research and commercial agreement with Australian ag giant Nufarm. The deal will see Moa receiving receive upfront payments, milestone development payments and royalties in return for Nufarm gaining exclusive access to a product in one of Moa's breakthrough novel mode of action areas.

Brandon Capital's vision for a transcontinental life science axis

Jonathan Tobin, Partner at Brandon Capital, discusses the firm's recent close of its sixth fund at A$270 million, bringing its total assets under management to over A$1.25 billion. He also explores how Brandon Capital is strategically connecting Australia, New Zealand, the UK, and the US.

Myricx Bio announces £90 million Series A financing to advance its novel NMTi-ADC therapeutics into clinical development

£90 million ($114 million) series A co-led by new leading life science investors Novo Holdings and Abingworth; additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners.

PIR International interview with Anja Harmeier, CEO, Rewind Therapeutics

In this blog, PIR International presents an interview with Anja Harmeier, CEO of Rewind Therapeutics, as part of their BioLeader interview series.

NCIMB Ltd kicks off innovative enzyme technology development project

Aberdeen-based biotechnology company NCIMB has kicked-off a new research project to demonstrate novel enzyme technology with an exciting array of potential applications in the pharmaceutical, food & drink and environmental sectors.

Promising results from cardiac fibrosis studies with MRX1

Ananda Developments PLC, a clinical-stage life sciences company focused on the development of CBD based therapies for the treatment of a range of complex inflammatory pain conditions, is delighted to share promising results from recent preclinical studies investigating the efficacy of MRX1 (Patent Pending) in treating cardiac fibrosis and heart failure with preserved ejection fraction (HFpEF).

Valneva Scotland appoints science communications consultancy, Perceptive Communicators

Glasgow-based specialist communications consultancy, Perceptive Communicators, has announced its appointment to provide strategic communications services for Valneva Scotland.

More within